Sionna is a high-stakes cystic fibrosis challenger: a cash-rich but pre-revenue biotech whose NBD1-stabilizing platform could disrupt Vertex—or collapse on pivotal clinical data.
Overview
Sionna Therapeutics is a pre-revenue clinical-stage biotech focused on cystic fibrosis, with a pipeline designed to normalize CFTR function by stabilizing the historically undruggable NBD1 domain. Its lead programs, SION-719 and SION-451, target the prevalent F508del mutation and may address the residual disease burden left by Trikafta. The investment case is highly binary: success could unlock meaningful share in a multibillion-dollar CFTR market, while failure would leave the company dependent on cash reserves and future financing.